Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
Pembrolizumab in combination with chemotherapy as conversion therapy for esophageal squamous cell carcinoma with cervical lymph node metastasis: A single-center, prospective, single-arm, open-label, ...
Efficacy and safety of nivolumab and CapeOX in patients with previously untreated FGFR2-positive, PD-L1-positive advanced gastric cancer: A single-arm, multicenter, phase 2 study NIVOFGFR2. This is an ...
Interim results from a phase 3 trial of AstraZeneca’s Imfinzi as a treatment before and after surgery in resectable non-small cell lung cancer (NSCLC) were head-scratching as they failed to answer two ...
The FDA should require clinical trials in perioperative therapy for non-small cell lung cancer (NSCLC) to address the individual contributions of neoadjuvant and adjuvant treatment to outcomes, an ...
Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder ...
Adding perioperative durvalumab (Imfinzi) to neoadjuvant chemotherapy significantly improved survival outcomes in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), a phase III ...
AstraZeneca announces perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in EFS and OS in MIBC in phase III VOLGA tr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results